0001209191-17-025569.txt : 20170405 0001209191-17-025569.hdr.sgml : 20170405 20170405160426 ACCESSION NUMBER: 0001209191-17-025569 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170403 FILED AS OF DATE: 20170405 DATE AS OF CHANGE: 20170405 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foundation Medicine, Inc. CENTRAL INDEX KEY: 0001488613 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 271316416 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 150 SECOND STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-418-2200 MAIL ADDRESS: STREET 1: 150 SECOND STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Daly David CENTRAL INDEX KEY: 0001320267 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36086 FILM NUMBER: 17742579 MAIL ADDRESS: STREET 1: 33171 PASEO CERVEZA CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-04-03 0 0001488613 Foundation Medicine, Inc. FMI 0001320267 Daly David C/O FOUNDATION MEDICINE, INC. 150 SECOND STREET CAMBRIDGE MA 02141 0 1 0 0 Chief Commercial Officer Common Stock 2017-04-03 4 S 0 2070 31.96 D 98582 D Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The reporting person previously reported the restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. /s/ Robert W. Hesslein, as Attorney-in-Fact for David Daly 2017-04-05